Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04824261
Other study ID # otomycosis
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2021
Est. completion date June 1, 2023

Study information

Verified date March 2021
Source Assiut University
Contact Maria H. Kamal
Phone +201275589149
Email dr.m.hosny.ent@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Otomycosis is a fungal infection that affects one, or occasionally both, of the ears. It mostly affects people who live in warm or tropical areas. It also often affects people who swim frequently, live with diabetes, or have other chronic medical and skin conditions. It is a pathologic entity, with candida and aspergillus the most common fungal species. ]Various predisposing factors include a humid climate, presence of cerumen, instrumentation of the ear, increased use of topical antibiotics / steroid preparations, immune-compromised host, patients who have undergone open cavity mastoidectomy and those who wear hearing aids with occlusive ear mold. The infection is usually unilateral and characterized by inflammatory pruritis, scaling and otalgia.Treatment recommendations have included local debridement, local and systemic antifungal agents and discontinuation of topical antibiotics. Sometimes otomycosis presents as a challenging disease for its long term treatment and follow up, yet its recurrence rate remains high. According to Thai National List of essential medicines for topical antifugal agents are: - acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol) - boric acid (4% in distilled water) - gentian violet - clotrimazole ear drop. Some fungal infections such as Aspergillus may be resistant to the usual ear drops. They may require oral medications.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date June 1, 2023
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Symptomatic otomycosis. - Microscopic direct examination and/or culture positive for fungus. Exclusion Criteria: - During usage of systemic antifungal drug - Allergic to 4% boric acid in distilled water or clotrimazole solution

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clotrimazol solution 1%
50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
4%boric acid in distilled water
50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Head Neck Surg. 2006 Nov;135(5):787-91. — View Citation

Kaur R, Mittal N, Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: a clinicomycologic study. Ear Nose Throat J. 2000 Aug;79(8):606-9. — View Citation

Mugliston T, O'Donoghue G. Otomycosis--a continuing problem. J Laryngol Otol. 1985 Apr;99(4):327-33. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Curative rate of otomycosis 1 month
See also
  Status Clinical Trial Phase
Completed NCT01993823 - Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis Phase 3
Completed NCT01547221 - Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients N/A
Recruiting NCT05660382 - Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis Phase 3
Completed NCT03686397 - SVT-15652 Otic Solution for the Treatment of Otomycosis. Phase 3
Not yet recruiting NCT06431542 - Efficacy of Self vs. Physician Application of Triamcinolone-Econazole in Otomycosis Phase 4
Completed NCT06339294 - Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment Phase 1
Completed NCT04432376 - Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) Phase 2/Phase 3
Completed NCT03686384 - SVT-15652 Otic Solution for the Treatment of Otomycosis Phase 3
Completed NCT04768829 - Antifungal Potential of Moringa Olifera Against Otomycosis Early Phase 1
Completed NCT03130738 - Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis Phase 2